MSLOF yields 3.37% · PFE yields 6.13%● Live data
📍 MSLOF pulled ahead of the other in Year 1
Combined, MSLOF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MSLOF + PFE for your $10,000?
Mitsui O.S.K. Lines, Ltd. engages in the marine transportation business in Japan and internationally. The company operates through Dry Bulk Business, Energy Transport Business, Product Transport Business, and Associated Businesses. Its fleet consists of dry bulk carriers for the transportation of iron ore, coal, grain, wood, wood chips, cement, fertilizer, and salt and steel products; crude oil tankers; tankers that transport refined petroleum products, such as gas oils, naphtha, and gasoline; chemical tankers that transport liquid chemical products; methanol carriers; and LPG carriers. The company's fleet also includes car carriers that transport passenger cars and construction machinery; containerships; and ferries and coastal RoRo ships. In addition, it operates container terminals; floating storage and regasification units; and floating production, storage, and offloading systems, as well as offers logistics services, such as air and ocean freight forwarding, trucking, customs clearance, warehousing, inspection, and heavyweight and oversized cargo transport, as well as buyers' consolidation. Further, the company is involved in ocean shipping related businesses comprising tugboat operation, land transport, maritime consulting, travel, office building leasing, property management, finance, trading, insurance, ICT systems, temporary staffing, supporting an oil stockpile project, nautical charts, and other businesses. As of March 31, 2021, it operated 268 dry bulkers; 280 tankers, LNG carriers, and steaming coal carriers; 60 containerships; 1 cruise ship; and 170 product transport vessels, as well as 2 other vessels. The company was founded in 1884 and is headquartered in Tokyo, Japan.
Full MSLOF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.